Skip to main content
. Author manuscript; available in PMC: 2019 Dec 1.
Published in final edited form as: Breast Cancer Res Treat. 2018 Sep 15;172(3):733–740. doi: 10.1007/s10549-018-4959-8

Figure 1b. Pathologic complete response rate (pCR) based on regimen and hormone receptor status (N = 121).

Figure 1b.

AC-THP, dose-dense doxorubicin/cyclophosphamide followed by paclitaxel or docetaxel plus pertuzumab and trastuzumab; THP, paclitaxel or docetaxel plus pertuzumab and trastuzumab; TCHP, docetaxel/carboplatin/trastuzumab/pertuzumab; AC-TH, dose-dense doxorubicin/cyclophosphamide followed by paclitaxel or docetaxel plus trastuzumab